MBRX
Moleculin Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.71
+5.09%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 8.0K | 90.0K | — | — | — |
| Gross Profit | (8.0K) | (90.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 19.7M | 15.9M | 17.7M | 19.5M | 19.0M |
| SG&A Expense | 9.1M | 9.1M | 8.8M | 10.0M | 11.5M |
| General & Admin Expense | 9.1M | 9.1M | 8.8M | 10.0M | 11.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 46.0K | 90.0K | 126.0K | 127.0K | 130.0K |
| Total Operating Expenses | 28.9M | 25.1M | 26.6M | 29.6M | 30.6M |
| Cost and Expenses | 28.9M | 25.1M | 26.6M | 29.6M | 30.6M |
| Operating Income (EBIT) | (28.9M) | (25.1M) | (26.6M) | (29.6M) | (30.6M) |
| Non-Operating | |||||
| Interest Income | 82.0K | 105.0K | 550.0K | 1.4M | 240.0K |
| Interest Expense | 78.0K | — | — | — | — |
| Net Interest Income | 4.0K | 105.0K | 550.0K | 1.4M | 240.0K |
| Other Non-Op Income/Expense | (1.5M) | (8.5M) | 4.9M | (138.0K) | 1.6M |
| Non-Operating Income (excl Interest) | 1.4M | 8.5M | (4.9M) | 138.0K | (1.6M) |
| EBT (Pre-Tax Income) | (30.3M) | (33.6M) | (21.8M) | (29.8M) | (29.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (30.3M) | (33.6M) | (21.8M) | (29.8M) | (29.0M) |
| Earnings from Cont. Ops | (30.3M) | (33.6M) | (21.8M) | (29.8M) | (29.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (32.5M) | (33.7M) | (21.8M) | (29.8M) | (29.0M) |
| Per Share | |||||
| Basic EPS | ($17.13) | ($28.42) | ($189.14) | ($376.71) | ($380.51) |
| Diluted EPS | ($17.13) | ($28.42) | ($189.14) | ($376.71) | ($380.51) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 5.7M | 1.2M | 137720 | 79024 | 76278 |
| Diluted Shares Outstanding | 5.7M | 1.2M | 137720 | 79024 | 76278 |
| Profitability Metrics | |||||
| EBITDA | (30.2M) | (33.5M) | (21.6M) | (29.6M) | (28.9M) |
| D&A | 47.0K | 90.0K | 126.0K | 127.0K | 130.0K |
| EBIT | (30.3M) | (33.6M) | (21.8M) | (29.8M) | (29.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026